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Neovasculature development is a crucial step in the natural history of a cancer. While much emphasis has been placed on
proangiogenic growth factors such as VEGF, it is clear that endogenous angiogenesis inhibitors also have critical roles in the regulation
of this process. Recent research has identified several cryptic fragments of extracellular matrix/vascular basement membrane proteins
that have potent antiangiogenic properties in vivo. It has become apparent that many of these fragments signal via interactions with
endothelial integrins, although multiple downstream effector pathways have been implicated and endostatin, the first non-collagenous
domain of collagen XVIII, influences an intricate signalling network. The activity of these molecules in animal models suggests that they
may have significant clinical activity; however, results of phase I/II trials with endostatin were disappointing. Many possible reasons can
be found for the failure of these studies. Weaknesses in trial design, endostatin administration regimen and patient selection are
identifiable, and importantly the lack of a clearly defined antiangiogenic mechanism for endostatin hindered assessment of biologically
effective dose. Additionally, in vivo immunological and proteolytic function-neutralising mechanisms may have negated endostatin’s
actions. Lessons learned from these studies will aid the future clinical development of other antiangiogenic extracellular matrix protein
fragments.
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Angiogenesis, the development of a neovasculature from pre-
existing blood vessels, is vital for tumour growth and metastasis.
Without a blood supply, neoplastic deposits remain dependent on
diffusion for nutrients, oxygenation and the removal of waste
metabolites. Their growth is restricted to a maximum of 1–2mm
3
and most remain clinically quiescent.
Interactions between endothelial cells and the extracellular
matrix (ECM), in particular components of the vascular basement
membrane (VBM), play key roles in the regulation of angiogenesis
(Kalluri, 2003). The VBM is constructed from interacting but
independent scaffolds of laminins and collagen IV complemented
by many other important but less abundant molecules such as
perlecan, the fibulins and collagens XV and XVIII. These molecules
contribute to the control of endothelial cell development,
proliferation, migration and function via interactions with
transmembrane signalling molecules such as the integrins and
syndecans.
While tumour angiogenesis is characterised by the secretion of a
multiplicity of proangiogenic factors tripping the angiogenic
switch resulting in the development of a structurally and
functionally abnormal vasculature, physiological angiogenesis is
tightly controlled and, in most tissues, proangiogenic factors are
balanced by endogenous antiangiogenic signals holding the
angiogenic switch ‘off’ (Carmeliet and Jain, 2000).
Recently, several ECM/VBM protein fragments have been
isolated that have potent antiangiogenic properties that are only
apparent after proteolytic cleavage of the fragments from their
parental molecule. These cryptic endogenous angiogenesis in-
hibitors (Nyberg et al, 2005) specifically inhibit endothelial cell
proliferation and migration in vitro and also have impressive
antitumour activity in vivo (O’Reilly et al, 1997; Hamano et al,
2003; Bix et al, 2004). These findings led to considerable
enthusiasm for the clinical investigation of the fragments.
However, this excitement has subsequently been tempered by the
results obtained in early phase trials of endostatin, a C-terminal
proteolytic fragment derived from the first non-collagenous (NC1)
domain of collagen XVIII (O’Reilly et al, 1997).
In this review, we will briefly describe the antiangiogenic
fragments of ECM proteins and then discuss the endostatin trials
focusing on what lessons can be learnt to aid us in the clinical
development of other endogenous angiogenesis inhibitors.
MECHANISMS OF ACTION – SIMILARITIES AND
DIFFERENCES
Since Homandberg et al (1985) isolated 29 and 40kDa fibro-
nectin fragments that could inhibit endothelial cell proliferation
(Homandberg et al, 1985), a substantial number of antiangiogenic
ECM protein fragments have been identified and these are
summarised in Table 1.
The most thoroughly investigated group of ECM fragments are
those derived from the first non-collagenous (NC1) domains of
VBM collagens – in particular, endostatin (O’Reilly et al, 1997) and
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from the a1 chain of collagen XVIII and a3 chain of collagen IV,
respectively. These globular, relatively protease-resistant domains
are released from the VBM by the action of proteolytic enzymes at
a protease-sensitive hinge region. While several proteases, includ-
ing elastase and cathepsin L, have been shown to induce endostatin
release in vitro, matrix metalloprotease-9 (MMP-9) appears to
generate tumstatin in vivo, as MMP-9 knockout mice have lower
circulating levels of tumstatin. Tumour xenografts exhibit rapid
growth with increased angiogenesis in these mice in a manner that
can be prevented by restoring ‘physiological’ serum tumstatin
levels (Hamano et al, 2003).
Recent research has identified that integrins on the endothelial
cell surface act as signal transducing receptors for many ECM
proteolytic fragments (Table 1). Endothelial cells express multiple
integrins but avb3 and a5b1 are substantially upregulated in
activated endothelia and antagonists of these transmembrane
receptors can suppress angiogenesis in vivo (summarised in Jin
and Varner, 2004). Tumstatin binds avb3 integrin and endostatin
binds a5b1, resulting in inhibition of downstream focal adhesion
kinase activation (Sudhakar et al, 2003) although the antiangio-
genic effector pathways are distinct for each molecule. Tumstatin
inhibits CAP-dependent protein translation via phosphatidylino-
sitol-3 kinase (PI3K)/Akt/mTOR and 4E-BP1, resulting in endo-
thelial cell apoptosis (Maeshima et al, 2001; Sudhakar et al, 2003).
Endostatin, however, modulates focal adhesion and actin stress
fibre formation. In human dermal microvascular cells (HDMECs),
endostatin induces clustering of a5b1 integrins within lipid raft
microdomains in a manner that is dependent on cell surface
heparan sulphate proteoglycans (HSPGs). This clustering activates
Src kinases that downregulate RhoA activity, so dissociating focal
adhesions and actin stress fibres and inhibiting endothelial cell
migration (Wickstro ¨m et al, 2003). Notably, the addition of a
second integrin-binding site to the N-terminal of endostatin
appears to increase its antiangiogenic potency (Yokoyama and
Ramakrishnan, 2004).
While this signalling pathway for endostatin has been well
elucidated, multiple other potential antiangiogenic mechanisms
and ligands for endostatin have been described. These include
direct interaction with cell surface KDR (Kim et al, 2002) and
glypican HSPGs (Karumanchi et al, 2001), binding to tropomyosin
isoform 3 (MacDonald et al, 2001), inhibition of MMP-2 (Lee et al,
2002) and downregulation of b-catenin via Wnt signalling path-
ways (Hanai et al, 2002). Notably, examination of the downstream
effects of endostatin in HDMECs by gene expression profiling and
phosphoproteomics (Abdollahi et al, 2004) detected the coordi-
nated regulation of eight angiogenic effector pathways with the
expression of 12% of assessed genes being altered at least two-fold
after 2h endostatin exposure. Although this investigation gives us
just a snapshot of the in vitro effects of a fixed concentration of
endostatin at a single time point in one endothelial cell line, it
demonstrates that endostatin influences a remarkable and intricate
signalling network in order to assert its antiangiogenic effects.
Clearly, further work needs to be performed to validate the data
and explore what factors allow endostatin to target tumour
endothelial cells specifically in animal models without adversely
affecting physiological angiogenesis. Similar investigations with
other ECM angiogenesis inhibitors may identify further simila-
rities or differences to endostatin, which could direct the
development of combination antiangiogenic approaches.
A PHYSIOLOGICAL ROLE?
Although a substantial body of evidence now exists to support an
antiangiogenic role for pharmacological doses of ECM fragments
in experimental systems, data indicating a physiological role for
these molecules are scarce. Endostatin is present at detectable
levels in the serum of normal individuals (Feldman et al, 2002;
IIzasa et al, 2004) and canstatin/arresten has been isolated from
human placenta, suggesting physiological function. Further
indirect evidence is provided by the study of mouse strains with
null mutations in the parental ECM molecule and rare single gene
disorders in humans (see Table 2). While these models implicate
ECM fragments such as endostatin and restin in vascular
development in specific organs, it appears that in the majority of
tissues there is ‘physiological redundancy’ with the absence of a
single fragment compensated for by other proteins.
Importantly however, Sund et al (2005) recently presented
evidence suggesting that tumstatin, endostatin and thrombospon-
din-1 have endogenous tumour suppressor functions. Using
tumstatin- and endostatin-deficient mouse strains, they documen-
ted accelerated growth of Lewis lung carcinoma/B16F10 melanoma
xenografts compared to identical tumours in the parental mouse
lines. Notably, tumour growth was even more rapid in mice
deficient in both tumstatin and thrombospondin-1, indicating that
these three molecules suppress the growth of tumour xenografts
when present at physiological concentrations. This observation
was reinforced by the observation that B16F10 xenograft growth
was suppressed in a mouse line engineered to overexpress
endostatin resulting in a 1.6-fold increase in circulating endostatin
levels. This latter model recapitulates the clinical observation that
Table 1 Proteolytic fragments of ECM components with antiangiogenic properties
Proteolytic fragment ECM protein Putative cell surface receptors Possible mechanisms of action
Collagen chain (NC1 domain)
Arresten a1 collagen IV a1b1 integrin and HSPG Interference with Ras–Shc–MAPK signalling
Canstatin a2 collagen IV avb3 integrin Downregulation of FLIP. Inhibition of PI3K/Akt signalling
Tumstatin a3 collagen IV avb3 and a6b1 integrins Inhibition of CAP-dependent protein synthesis
a6 NC1 a6 collagen IV avb3 integrin ND
Endostatin a1 collagen XVIII a5b1 integrins and HSPGs See text
Restin a1 collagen XV ND ND
Vastatin a1 collagen VIII ND ND
Other ECM proteins
Anastellin First type III repeat of fibronectin ND Inhibition of ERK signalling
Endorepellin Perlecan a2b1 integrin Upregulation of PKA and FAK activity
TSP-1 fragments Thrombospondin-1 CD36/ b1-integrins Inhibition of PI3K
PEX MMP-2 avb3 integrin Blocks cell surface activity of MMP-2
ECM¼extracellular matrix; HSPG¼heparan sulphate proteoglycan; MAPK¼mitogen-activated protein kinase; PI3K¼phosphatidylinositol-3 kinase; ND¼not defined;
ERK¼extracellular signal-regulated kinase; FAK¼focal adhesion kinase; PKA¼protein kinase A; MMP-2¼matrix metalloproteinase-2; Nyberg et al (2005) and references
therein.
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copies of the collagen XVIII gene and 70% higher serum
endostatin levels (Zorick et al, 2001) have much lower standar-
dised mortality odds ratios for death from solid malignant
tumours at all ages than the rest of the population (Yang et al,
2002), suggesting that endostatin may have an endothelium-
specific tumour suppressor function in humans.
CLINICAL STUDIES
While most antiangiogenic ECM fragments have yet to enter
clinical development, three phase I trials have been published
using recombinant human endostatin in a total of 61 patients with
advanced metastatic cancer (including 11 melanoma, 10 sarcoma,
nine colorectal, nine lung, seven breast, four renal) (Eder et al,
2002; Herbst et al, 2002a; Thomas et al, 2003). These studies
administered daily endostatin doses of 15–600mgm
 2day
 1 by
short intravenous infusion. No significant endostatin-related
toxicity was noted. Endostatin displayed consistent linear phar-
macokinetics with the area under the serum concentration–time
curve reaching levels associated with activity in animal models, at
doses of 300mgm
 2day
 1. No formal disease responses were seen
although some evidence of antineoplastic activity was noted with
one patient with metastatic pancreatic neuroendocrine tumour
experiencing a minor response (Eder et al, 2002). However, these
suggestions of antitumour activity did not appear to be dose-
related and a subsequent phase II study of twice daily
subcutaneous endostatin in metastatic neuroendocrine tumours
only documented two minor responses in 41 patients (Kulke et al,
2003).
One problem for the phase I development of all antiangiogenic
agents, which is exemplified by endostatin, is the difficulty in
establishing the biologically effective dose (BED). All three phase I
studies utilised radiological and biopsy-based indicators of tumour
angiogenesis to assess BED. Thomas et al (2003) failed to
demonstrate any significant changes by in vivo imaging with
dynamic CT (marker of microvessel density), dynamic MRI
(marker of tumour blood flow) or [
18F]FDG PET (measure of
tumour glucose metabolism). No changes in microvessel density,
endothelial cell apoptosis, proliferation or vessel maturity were
seen in paired pre- and 8-week post-treatment tumour biopsies
from patients in this study although only eight sample pairs were
available for analysis.
Herbst et al (2002b), however, in their study of 26 patients
detected complex effects on tumour blood flow and biopsy
biomarkers of tumour angiogenesis. Utilising [
15O]H2O PET, they
noted that blood flow decreased by an average of 20% with
endostatin treatment by day 28 at the 180mgm
 2day
 1 dose level.
Subtle changes in intratumoral glucose metabolism were also
noted at higher endostatin doses. Changes in intratumoral blood
flow only reached statistical significance however if patients
treated at the 30mgm
 2day
 1 dose level were included. These
patients did not have baseline PET imaging and so changes during
cycle 2 instead of cycle 1 were used in the assessment of this
cohort. Tumour biopsy analysis for microvessel density, endo-
thelial cell apoptosis and nuclear localisation of HIF-1a as a
marker of tumour hypoxia also suggested that endostatin
was having an in vivo biological effect on human cancer (Davis
et al, 2004). Intriguingly, statistical analysis using the quadratic
polynomial model indicated that these effects may have a
U-shaped relationship with dose, being most apparent around
250mgm
 2day
 1. While such exploratory analyses give us a
potential insight into a BED for endostatin, they should be
interpreted cautiously for several reasons. It is possible that
the analysis employed was highly dependent on the range of doses
used and may be distorted by the presence of outlying values.
Seven patients (28%) with early progressive disease on study were
excluded from these analyses owing to a lack of post-treatment
biopsies and most importantly, these signs of biological activity
were not translated into clinical activity. It is also impossible to
rule out a contribution of tumour biology to the changes
documented as no information is available on the natural history
of these parameters in untreated malignancy.
WHAT CAN BE LEARNED FROM THE ENDOSTATIN
TRIALS?
Although the studies discussed above confirmed the safety of
endostatin as a pharmacological agent, the lack of antineoplastic
and antiangiogenic activity was disappointing. What lessons can
be drawn from these studies for the future clinical development of
endostatin and other endogenous angiogenesis inhibitors?
Appropriate trial design, administration regimen and
patient selection
Conventionally, most phase I studies are conducted in patients
with bulky chemotherapy-resistant metastatic disease. Such
patients are not ideal for the assessment of antiangiogenic agents,
as not only do the tumours already have an established vasculature
but the cancer cells are likely to have become tolerant of hypoxia
and other apoptosis-inducing signals. It may be more appropriate,
once toxicity data are available, to assess these agents in patients
with minimal residual disease.
Endostatin was administered as short daily intravenous infu-
sions in the published phase I studies. However, initial animal data
were generated using the subcutaneous administration of a poorly
soluble form of endostatin that is likely to have acted as a depot
(O’Reilly et al, 1997) and subsequent work has shown that
continuous infusion of endostatin is markedly more effective than
bolus administration in animal models (Kisker et al, 2001). The
most efficacious preclinical regimen should be adopted in clinical
studies if feasible.
Tumour response may also be an inappropriate end point in
phase II studies of endogenous angiogenesis inhibitors, as such
molecules may only result in disease stabilisation. Trial designs
Table 2 Phenotypic manifestations associated with the deletion of ECM proteins
ECM protein Associated fragment Phenotype
Collagen XVIII Endostatin Knobloch’s syndrome – myopia, vitreoretinal degeneration, occipital encephalocoele
Knockout mouse – abnormal ocular vasculature
Collagen XV Restin Knockout mouse – skeletal myopathy, abnormal cardiac and skeletal muscle capillaries
Collagen IVa3 Tumstatin Alport’s syndrome – haematuria, proteinuria, renal failure, sensorineural deafness
Knockout mouse – renal failure secondary to glomerular basement membrane abnormalities, more rapid
growth and increased vascularisation of tumour xenografts
Perlecan Endorepellin Knockout mouse – embryonic death, intrapericardial haemorrhage and cardiac developmental abnormalities
ECM¼extracellular matrix; Hudson et al (2003), Marneros and Olsen (2005) and Nyberg et al (2005).
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discontinuation model (Rosner et al, 2002) may be more sensitive
to a biological effect.
Clear understanding of antiangiogenic mechanism
At the time of the design of the endostatin trials, very little was
known about endostatin’s mechanisms of action. This clearly
inhibited the scope of biomarker/translational research under-
taken. The complexity of signalling pathways modulated by
endostatin in endothelial cells in vitro means that no single
biomarker can be proposed with certainty for investigation in
future trials although assessment of a5b1 integrin expression and
downstream signalling should be considered. The emerging
evidence for a role of cell surface HSPGs in endostatin’s function
means that the use of heparin, particularly as a line-lock, may have
abrogated its clinical activity. Such treatment was specifically
contra-indicated in only one trial (Herbst et al, 2002a).
The clearly defined antiangiogenic mechanism for tumstatin
indicates that assessment of PI3K–mTOR–4E-BP1 pathway in
tumour endothelial cells should be included as a pharmaco-
dynamic end point in any phase I tumstatin trials.
Immunogenicity, intravascular proteolysis and a potential
platelet sink
The administration of exogenous protein is associated with an
immunogenic risk. Although no significant allergic reactions were
seen with endostatin, many patients rapidly developed anti-
endostatin IgG titres (Eder et al, 2002; Herbst et al, 2002a).
Whether these antibodies are function-neutralising is not clear but
their rapid induction is concerning.
Another immunological factor that may impinge on the clinical
development of tumstatin is the localisation of the epitope
recognised by the pathogenic auto-antibodies for Goodpasture’s
syndrome (GPS), a condition characterised by rapidly progressive
glomerulonephritis and pulmonary haemorrhage, at the N-
terminus of the tumstatin domain of a3 collagen IV (Hudson
et al, 2003).
The potential clearance of circulating proteins by plasma and
ECM proteases is a concern with all endogenous antiangiogenics.
Although pharmacokinetic data were linear and analysis of serum-
isolated endostatin in one phase I study (Thomas et al, 2003) did
not demonstrate extensive proteolytic degradation, small shifts in
mass spectrometry profiles were noted that could be consistent
with limited terminal proteolytic cleavage. Of note, no in vitro
activity could be demonstrated for re-isolated endostatin in any of
the three studies.
In addition, platelets sequester many angiogenic regulators and
have recently been shown to take up endostatin in a selective and
quantifiable manner (Klement et al, 2004). This may indicate that
the circulating platelet mass may need to become saturated with




Many established tumours have blood vessels lined in part or
completely by tumour cells. In some cases, these cells express
surface markers normally confined to endothelial cells. Tubular
network formation by such cell lines is unaffected by endostatin
treatment and other angiogenesis inhibitors (van der Schaft et al,
2004), indicating that the vascularity of some tumours may not be
altered even if optimal inhibition of endothelial cell function is
achieved in vivo. Some lung carcinomas also co-opt the host’s
existing alveolar capillary network. They are therefore less reliant
on neoangiogenesis and unlikely to be sensitive to antiangiogenic
therapies (Pezzella et al, 1997).
Targeting an already overloaded system
Elevated serum endostatin concentration is seen in many
untreated cancer patients and has been identified as an adverse
prognostic factor. It is unclear whether these elevated endostatin
levels are due to direct intratumoral production or a coordinated
‘host’ response to proangiogenic stimuli, in particular VEGF
produced by the cancer (Feldman et al, 2002; Glenjen et al, 2002;
Iizasa et al, 2004). What such findings do suggest however is that if
this endogenous endostatin is in an active form, further increasing
serum endostatin levels to pharmacological levels may not have a
significant additional antiangiogenic effect as it is possible that in
clinically manifest tumours, once the angiogenic switch has been
tripped, raising the levels of endogenous antiangiogenic agents
further is not very effective in resetting this. A further alternative
explanation is that in effect these cancers are already at the top of
the dose–response curve for endostatin and so have overcome its
inhibitory effects. This possibility would have significant implica-




Preclinical studies have demonstrated that the antitumour effects
of endostatin are additive to radiotherapy (Shi et al, 2003) and
synergistic with cytotoxic chemotherapy (Plum et al, 2003) in
animal models. Importantly, no exacerbation of treatment-related
toxicity was seen. Importantly, the recently reported preliminary
results of a Chinese phase III trial appear to confirm these findings
in man. The administration of a novel recombinant endostatin
produced in Escherichia coli (Endostart) in combination with
chemotherapy in advanced non-small-cell lung cancer significantly
increased response rates and time to progression when compared
to chemotherapy alone (Sun et al, 2005). Publication of the full
results is eagerly awaited.
More intriguingly, several studies have demonstrated synergy
between endostatin and other antiangiogenic agents. Rational
combinations determined by analysis of microarray data have been
tested successfully in animal models. Cline et al (2002) noted
markedly different gene expression profiles when endothelial cells
were treated with TNP-470, a synthetic fumagillin analogue, or
endostatin and subsequently showed synergistic activity with these
agents against Lewis lung carcinoma xenografts. The results of
Abdollahi et al (2004) indicated that endostatin downregulated
many of the key mediators of VEGF signalling and notably,
endostatin and SU5416, a small molecule tyrosine kinase inhibitor
of KDR, are synergistic in inhibiting endothelial cell proliferation
and the growth and vascularisation of tumour xenografts
(Abdollahi et al, 2003). Tumours also grow more rapidly in double
tumstatin/TSP-1 knockouts than in mice lacking only one of these
molecules, suggesting a broader applicability of the concept of
combined antiangiogenic therapy (Sund et al, 2005).
Peptide fragments
One potential problem with the clinical development of antiangio-
genic ECM proteolytic fragments is the requirement to synthesise
large quantities of pharmaceutical grade protein. One way of
reducing these manufacturing costs may be to identify component
peptides from within these molecules that retain antiangiogenic
activity. For example, a modified nonapeptide, ABT-510, derived
from the second type-1 repeat of TSP-1 has shown promising
preclinical and clinical antiangiogenic activity (Haviv et al, 2005).
ECM protein fragments
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mimicked by a peptide encompassing amino acids 54–132
(Maeshima et al, 2001). The loss of the N-terminal domain of
tumstatin in this peptide is potentially of clinical importance as
this removes the epitope responsible for GPS.
Endostatin-derived peptides have also been investigated. How-
ever, the antiangiogenic activity has been shown to reside in
different regions of the molecule by different groups. For instance,
a peptide encompassing the secondary heparin-binding site was
the minimal active domain in one in vivo study (Olsson et al, 2004)
and the N-terminal 29 amino acids critical in another (Tjin Tham
Sjin et al, 2005). While both peptides are antiangiogenic, it is not
clear whether they function by the same intracellular effector
pathways as each other or as parental endostatin.
CONCLUSIONS
The identification of a series of cryptic proteolytic fragments of
ECM components as endogenous angiogenesis inhibitors has shed
new light on our understanding of the control of blood vessel
development (Nyberg et al, 2005). It is intriguing that integrin-
dependent signalling pathways have emerged as critical down-
stream mediators of the antiangiogenic properties of many of these
fragments and that endostatin induces a profound, coordinated
response in the angiogenic gene expression profile of endothelial
cells (Abdollahi et al, 2004).
The discovery of these molecules has also opened
up a significant new avenue in the development of antineoplastic
agents. While the clinical development of endostatin as an
antiangiogenic drug to date has been disappointing, it has enabled
us to learn a number of lessons that could improve the
strategy used to take other fragments, for instance tumstatin,
through to the clinic. It is desirable that careful biological assays
are conducted in a variety of systems and that a defined
mechanism of action has been elucidated prior to clinical trials
so that trial design can be targeted and appropriate candidate
biomarkers can be selected for testing alongside conventional
toxicity screening.
The ultimate future of these ECM-derived angiogenesis inhibi-
tors may however lie in the development of rational combinations
either with conventional antineoplastic therapy or other anti-
angiogenic agents.
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